Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 157

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Lipid-modifying effects of nutraceuticals: An evidence-based approach

Sahebkar, Amirhossein, Serban, Maria-Corina, Gluba-Brzózka, Anna, Mikhailidis, Dimitri P., Cicero, Arrigo F., Rysz, Jacek, Banach, Maciej·2016·Nutrition
DOI 10.1016/j.nut.2016.04.007
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.nut.2016.04.007

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Research works printed but not linked: 186

  1. Chen, 2014, Nutraceuticals and functional foods in the management of hyperlipidemia, Crit Rev Food Sci Nutr, 54, 1180, 10.1080/10408398.2011.629354 · DOI
  2. Sahebkar, 2014, Role of selective peroxisome proliferator-activated receptor modulators in managing cardiometabolic disease: tale of a roller-coaster, Diabetes Obes Metab, 16, 780, 10.1111/dom.12277 · DOI
  3. Sahebkar, 2014, New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease, Expert Opin Pharmacother, 15, 493, 10.1517/14656566.2014.876992 · DOI
  4. Banach, 2014, Lipid, blood pressure and kidney update 2013, Int Urol Nephrol, 46, 947, 10.1007/s11255-014-0657-6 · DOI
  5. Sahebkar, 2014, Recent advances in pharmacotherapy for hypertriglyceridemia, Prog Lipid Res, 56, 47, 10.1016/j.plipres.2014.07.002 · DOI
  6. Sahebkar, 2013, New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes, Clin Ther, 35, 1082, 10.1016/j.clinthera.2013.06.019 · DOI
  7. Sahebkar, 2013, New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect?, Cardiovasc Drugs Ther, 27, 559, 10.1007/s10557-013-6479-4 · DOI
  8. Fruchart, 2008, The residual risk reduction initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia, Am J Cardiol, 102, 1K, 10.1016/j.amjcard.2008.10.002 · DOI · Paper page
  9. Hermans, 2009, Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries, Curr Med Res Opin, 26, 445, 10.1185/03007990903500565 · DOI
  10. Leiter, 2011, Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study, Diabet Med, 28, 1343, 10.1111/j.1464-5491.2011.03360.x · DOI
  11. Toth, 2014, Should low high-density lipoprotein cholesterol (HDL-C) be treated?, Best Pract Res Clin Endocrinol Metab, 28, 353, 10.1016/j.beem.2013.11.002 · DOI
  12. Rizzo, 2013, Combined dyslipidemia: should the focus be LDL cholesterol or atherogenic dyslipidemia?, Curr Pharm Des, 19, 3858, 10.2174/13816128113199990324 · DOI
  13. Scicchitano, 2014, Nutraceuticals and dyslipidaemia: beyond the common therapeutics, J Funct Foods, 6, 11, 10.1016/j.jff.2013.12.006 · DOI · Paper page
  14. Houston, 2012, The role of nutraceutical supplements in the treatment of dyslipidemia, J Clin Hyertens (Greenwich), 14, 121, 10.1111/j.1751-7176.2011.00576.x · DOI
  15. Banach, 2015, Lipids, blood pressure and kidney update 2014, Pharm Res, 95–6, 111, 10.1016/j.phrs.2015.03.009 · DOI
  16. 2001, Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on Detection, Evaluation, and Treatment of high blood cholesterol in adults (Adult Treatment Panel III), JAMA, 285, 2486, 10.1001/jama.285.19.2486 · DOI · Paper page
  17. Cicero, 2012, Tolerability and safety of commonly used dietary supplements and nutraceuticals with lipid-lowering effects, Expert Opin Drug Saf, 11, 753, 10.1517/14740338.2012.705827 · DOI
  18. Badimon, 2010, Nutraceuticals and atherosclerosis: human trials, Cardiovasc Ther, 28, 202, 10.1111/j.1755-5922.2010.00189.x · DOI
  19. Garcia-Rios, 2013, Nutraceuticals and coronary heart disease, Curr Opin Cardiol, 28, 475, 10.1097/HCO.0b013e32836081a5 · DOI
  20. Wu, 2009, The effects of phytosterols/stanols on blood lipid profiles: a systematic review with meta-analysis, Asia Pac J Clin Nutr, 18, 179
  21. Dong, 2013, The effects of berberine on blood lipids: a systemic review and meta-analysis of randomized controlled trials, Planta Med, 79, 437, 10.1055/s-0032-1328321 · DOI · Paper page
  22. Sahebkar, 2013, Effects of resveratrol supplementation on plasma lipids: a systematic review and meta-analysis of randomized controlled trials, Nutr Rev, 71, 822, 10.1111/nure.12081 · DOI
  23. Sahebkar, 2014, A systematic review and meta-analysis of randomized controlled trials investigating the effects of curcumin on blood lipid levels, Clin Nutr, 33, 406, 10.1016/j.clnu.2013.09.012 · DOI
  24. Wallace, 2016, Systematic review of anthocyanins and markers of cardiovascular disease, Nutrients, 8, 32, 10.3390/nu8010032 · DOI
  25. Aziz, 2013, Effects of Hibiscus sabdariffa L. on serum lipids: a systematic review and meta-analysis, J Ethnopharmacol, 150, 442, 10.1016/j.jep.2013.09.042 · DOI · Paper page
  26. Zhu, 2014, Effects of fish oil on serum lipid profile in dialysis patients: a systematic review and meta-analysis of randomized controlled trials, Lipids Health Dis, 13, 127, 10.1186/1476-511X-13-127 · DOI
  27. Derakhshande-Rishehri, 2015, Association of foods enriched in conjugated linoleic acid (CLA) and CLA supplements with lipid profile in human studies: a systematic review and meta-analysis, Public Health Nutr, 18, 2041, 10.1017/S1368980014002262 · DOI
  28. Guo, 2011, Influence of consumption of probiotics on the plasma lipid profile: a meta-analysis of randomised controlled trials, Nutr Metab Cardiovasc Dis, 21, 844, 10.1016/j.numecd.2011.04.008 · DOI
  29. Baker, 2008, A meta-analysis evaluating the impact of chitosan on serum lipids in hypercholesterolemic patients, Ann Nutr Metab, 55, 368, 10.1159/000258633 · DOI
  30. Chua, 2010, Traditional uses and potential health benefits of Amorphophallus konjac K. Koch ex N.E.Br, J Ethnopharmacol, 128, 268, 10.1016/j.jep.2010.01.021 · DOI · Paper page
  31. Klingberg, 2007, Food sources of plant sterols in the EPIC Norfolk population, Eur J Clin Nutr, 62, 695, 10.1038/sj.ejcn.1602765 · DOI
  32. Valsta, 2004, Estimation of plant sterol and cholesterol intake in Finland: quality of new values and their effect on intake, Br J Nutr, 92, 671, 10.1079/BJN20041234 · DOI
  33. Klingberg, 2008, Inverse relation between dietary intake of naturally occurring plant sterols and serum cholesterol in northern Sweden, Am J Clin Nutr, 87, 993, 10.1093/ajcn/87.4.993 · DOI
  34. Sioen, 2011, Consumption of plant sterols in Belgium: estimated intakes and sources of naturally occurring plant sterols and β-carotene, Br J Nutr, 105, 960, 10.1017/S0007114510004587 · DOI
  35. Jiménez-Escrig, 2006, Common sources and estimated intake of plant sterols in the Spanish diet, J Agric Food Chem, 54, 3462, 10.1021/jf053188k · DOI
  36. Jenkins, 2001, Effect of a very-high-fiber vegetable, fruit, and nut diet on serum lipids and colonic function, Metabolism, 50, 494, 10.1053/meta.2001.21037 · DOI
  37. Racette, 2009, Phytosterol-deficient and high-phytosterol diets developed for controlled feeding studies, J Am Diet Assoc, 109, 2043, 10.1016/j.jada.2009.09.009 · DOI
  38. Nissinen, 2002, Micellar distribution of cholesterol and phytosterols after duodenal plant stanol ester infusion, Am J Physiol Gastrointest Liver Physiol, 282, G1009, 10.1152/ajpgi.00446.2001 · DOI
  39. Smet, 2012, Effects of plant sterols and stanols on intestinal cholesterol metabolism: suggested mechanisms from past to present, Mol Nutr Food Res, 56, 1058, 10.1002/mnfr.201100722 · DOI · Paper page
  40. Calandra, 2011, Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk, J Lipid Res, 52, 1885, 10.1194/jlr.R017855 · DOI
  41. Dragan, 2014, Can we change the functionality of HDL cholesterol with nonpharmacological and pharmacological agents?, Curr Med Chem, 21, 2927, 10.2174/0929867321666140303153829 · DOI
  42. Amir Shaghaghi, 2013, Cholesterol-lowering efficacy of plant sterols/stanols provided in capsule and tablet formats: results of a systematic review and meta-analysis, J Acad Nutr Diet, 113, 1494, 10.1016/j.jand.2013.07.006 · DOI · Paper page
  43. Fransen, 2007, Customary use of plant sterol and plant stanol enriched margarine is associated with changes in serum plant sterol and stanol concentrations in humans, J Nutr, 137, 1301, 10.1093/jn/137.5.1301 · DOI
  44. Assmann, 2006, Plasma sitosterol elevations are associated with an increased incidence of coronary events in men: results of a nested case–control analysis of the Prospective Cardiovascular Münster (PROCAM) study, Nutr Metab Cardiovasc Dis, 16, 13, 10.1016/j.numecd.2005.04.001 · DOI · Paper page
  45. Silbernagel, 2010, The associations of cholesterol metabolism and plasma plant sterols with all-cause and cardiovascular mortality, J Lipid Res, 51, 2384, 10.1194/jlr.P002899 · DOI
  46. Tilvis, 1986, Serum plant sterols and their relation to cholesterol absorption, Am J Clin Nutr, 43, 92, 10.1093/ajcn/43.1.92 · DOI · Paper page
  47. Plat, 2006, Plant sterol or stanol esters retard lesion formation in LDL receptor-deficient mice independent of changes in serum plant sterols, J Lipid Res, 47, 2762, 10.1194/jlr.M600346-JLR200 · DOI
  48. Silbernagel, 2009, The relationships of cholesterol metabolism and plasma plant sterols with the severity of coronary artery disease, J Lipid Res, 50, 334, 10.1194/jlr.P800013-JLR200 · DOI
  49. Párraga-Martínez, 2015, Long-term effects of plant stanols on the lipid profile of patients with hypercholesterolemia. A randomized clinical trial, Rev Esp Cardiol, 68, 665, 10.1016/j.recesp.2014.07.036 · DOI
  50. Vásquez-Trespalacios, 2014, Efficacy of yogurt drink with added plant stanol esters (Benecol®, Colanta) in reducing total and LDL cholesterol in subjects with moderate hypercholesterolemia: a randomized placebo-controlled crossover trial NCT01461798, Lipids Health Dis, 13, 125, 10.1186/1476-511X-13-125 · DOI
  51. Gupta, 2014, Alkaloids as aldose reductase inhibitors, with special reference to berberine, J Altern Complement Med, 20, 195, 10.1089/acm.2013.0088 · DOI
  52. Yin, 2008, Traditional Chinese medicine in treatment of metabolic syndrome, Endocr Metab Immune Disord Drug Targets, 8, 99, 10.2174/187153008784534330 · DOI · Paper page
  53. Lee, 2007, Berberine-induced LDLR up-regulation involves JNK pathway, Biochem Biophys Res Commun, 362, 853, 10.1016/j.bbrc.2007.08.060 · DOI
  54. Cameron, 2008, Berberine decreases PCSK9 expression in HepG2 cells, Atherosclerosis, 201, 266, 10.1016/j.atherosclerosis.2008.02.004 · DOI · Paper page
  55. Dragan, 2015, Proprotein convertase subtilisin/kexin 9 inhibitors an emerging lipid-lowering therapy?, J Cardiovasc Pharmacol Ther, 20, 157, 10.1177/1074248414539562 · DOI
  56. Banach, 2013, PCSK9 inhibition-a novel mechanism to treat lipid disorders?, Curr Pharm Des, 19, 3869, 10.2174/13816128113199990303 · DOI
  57. Brusq, 2006, Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine, J Lipid Res, 47, 1281, 10.1194/jlr.M600020-JLR200 · DOI · Paper page
  58. Kong, 2008, Combination of simvastatin with berberine improves the lipid-lowering efficacy, Metabolism, 57, 1029, 10.1016/j.metabol.2008.01.037 · DOI
  59. Vrzal, 2005, Activation of the aryl hydrocarbon receptor by berberine in HepG2 and H4 IIE cells: biphasic effect on CYP1 A1, Biochem Pharmacol, 70, 925, 10.1016/j.bcp.2005.06.016 · DOI
  60. Affuso, 2010, Cardiovascular and metabolic effects of Berberine, World J Cardiol, 2, 71, 10.4330/wjc.v2.i4.71 · DOI
  61. Chan, 1993, Displacement of bilirubin from albumin by berberine, Biol Neonate, 63, 201, 10.1159/000243932 · DOI
  62. Ma, 2000, Constituents of red yeast rice, a traditional Chinese food and medicine, J Agric Food Chem, 48, 5220, 10.1021/jf000338c · DOI · Paper page
  63. Arunachalam, 2011, Monascus fermented rice and its beneficial aspects: a new review, Asian J Pharm Clin Res, 4, 29
  64. Chen, 2013, Improved dissolution rate and oral bioavailability of lovastatin in red yeast rice products, Int J Pharm, 444, 18, 10.1016/j.ijpharm.2013.01.028 · DOI
  65. Heber, 1999, Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement, Am J Clin Nutr, 69, 231, 10.1093/ajcn/69.2.231 · DOI · Paper page
  66. Becker, 2009, Red yeast rice for dyslipidemia in statin-intolerant patientsa randomized trial, Ann Intern Med, 150, 830, 10.7326/0003-4819-150-12-200906160-00006 · DOI · Paper page
  67. Chung, 2014, Is red yeast rice capsule beneficial for treating dyslipidemia amongst statin-intolerant patients as compared to placebo?, Adv Integr Med, 1, 151, 10.1016/j.aimed.2014.06.001 · DOI
  68. Cicero, 2005, Antihyperlipidaemic effect of a Monascus purpureus brand dietary supplement on a large sample of subjects at low risk for cardiovascular disease: a pilot study, Complement Ther Med, 13, 273, 10.1016/j.ctim.2005.07.008 · DOI
  69. Keithley, 2002, A pilot study of the safety and efficacy of cholestin in treating HIV-related dyslipidemia, Nutrition, 18, 201, 10.1016/S0899-9007(01)00688-8 · DOI
  70. Gheith, 2008, Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidemia, Clin Exp Nephrol, 12, 189, 10.1007/s10157-008-0033-x · DOI
  71. Li, 2009, Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS), J Clin Pharmacol, 49, 947, 10.1177/0091270009337509 · DOI
  72. Lin, 2005, Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia, Eur J Endocrinol, 153, 679, 10.1530/eje.1.02012 · DOI
  73. Venero, 2010, Lipid-lowering efficacy of red yeast rice in a population intolerant to statins, Am J Cardiol, 105, 664, 10.1016/j.amjcard.2009.10.045 · DOI
  74. Hansen, 2005, Outcomes in 45 patients with statin-associated myopathy, Arch Intern Med, 165, 2671, 10.1001/archinte.165.22.2671 · DOI · Paper page
  75. Chen, 2011, Interaction between red yeast rice and CYP450 enzymes/P-glycoprotein and its implication for the clinical pharmacokinetics of lovastatin, Evid Based Complement Alternat Med, 2012, 127043
  76. Sahebkar, 2016, Effect of garlic on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of randomized controlled clinical trials, Nutrition, 32, 33, 10.1016/j.nut.2015.06.009 · DOI · Paper page
  77. Warshafsky, 1993, Effect of garlic on total serum cholesterol: a meta-analysis, Ann Intern Med, 119, 599, 10.7326/0003-4819-119-7_Part_1-199310010-00009 · DOI · Paper page
  78. Silagy, 1994, A meta-analysis of the effect of garlic on blood pressure, J Hypertens, 12, 463, 10.1097/00004872-199404000-00017 · DOI · Paper page
  79. Stevinson, 2000, Garlic for treating hypercholesterolemia: a meta-analysis of randomized clinical trials, Ann Intern Med, 133, 420, 10.7326/0003-4819-133-6-200009190-00009 · DOI · Paper page
  80. Khoo, 2009, Garlic supplementation and serum cholesterol: a meta-analysis, J Clin Pharm Ther, 34, 133, 10.1111/j.1365-2710.2008.00998.x · DOI
  81. Reinhart, 2009, The impact of garlic on lipid parameters: a systematic review and meta-analysis, Nutr Res Rev, 22, 39, 10.1017/S0954422409350003 · DOI
  82. Zeng, 2012, A meta-analysis of randomized, double-blind, placebo-controlled trials for the effects of garlic on serum lipid profiles, J Sci Food Agric, 92, 1892, 10.1002/jsfa.5557 · DOI
  83. Gardner, 2007, Effect of raw garlic vs commercial garlic supplements on plasma lipid concentrations in adults with moderate hypercholesterolemia: a randomized clinical trial, Arch Intern Med, 167, 346, 10.1001/archinte.167.4.346 · DOI
  84. Liu, 2002, S-alk (en) yl cysteines of garlic inhibit cholesterol synthesis by deactivating HMG-CoA reductase in cultured rat hepatocytes, J Nutr, 132, 1129, 10.1093/jn/132.6.1129 · DOI
  85. Kwon, 2003, Cholesteryl ester transfer protein activity and atherogenic parameters in rabbits supplemented with cholesterol and garlic powder, Life Sci, 72, 2953, 10.1016/S0024-3205(03)00234-0 · DOI
  86. Amagase, 2006, Clarifying the real bioactive constituents of garlic, J Nutr, 136, 716S, 10.1093/jn/136.3.716S · DOI · Paper page
  87. Rahman, 2006, Garlic and cardiovascular disease: a critical review, J Nutr, 136, 736S, 10.1093/jn/136.3.736S · DOI · Paper page
  88. Borriello, 2014, Resveratrol: from basic studies to bedside, Cancer Treat Res, 159, 167, 10.1007/978-3-642-38007-5_10 · DOI
  89. Chow, 2014, A pilot clinical study of resveratrol in postmenopausal women with high body mass index: effects on systemic sex steroid hormones, J Transl Med, 12, 223, 10.1186/s12967-014-0223-0 · DOI
  90. Witte, 2014, Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults, J Neurosci, 34, 7862, 10.1523/JNEUROSCI.0385-14.2014 · DOI · Paper page
  91. Chachay, 2014, Resveratrol does not benefit patients with nonalcoholic fatty liver disease, Clin Gastoenterol Hepatol, 12, 2092, 10.1016/j.cgh.2014.02.024 · DOI · Paper page
  92. Liu, 2015, Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials, Clin Nutr, 34, 27, 10.1016/j.clnu.2014.03.009 · DOI
  93. Sahebkar, 2015, Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular parameters: results from a systematic review and meta-analysis of randomized controlled trials, Int J Cardiol, 189, 47, 10.1016/j.ijcard.2015.04.008 · DOI
  94. Carrizzo, 2013, Antioxidant effects of resveratrol in cardiovascular, cerebral and metabolic diseases, Food Chem Toxicol, 61, 215, 10.1016/j.fct.2013.07.021 · DOI · Paper page
  95. Liu, 2014, Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials, Am J Clin Nutr, 99, 1510, 10.3945/ajcn.113.082024 · DOI · Paper page
  96. Mohagheghi, 2010, The effect of Hibiscus sabdariffa on lipid profile, creatinine, and serum electrolytes: a randomized clinical trial, ISRN Gastroenter, 2011, 976019
  97. Sindi, 2014, Comparative chemical and biochemical analysis of extracts of Hibiscus sabdariffa, Food Chem, 164, 23, 10.1016/j.foodchem.2014.04.097 · DOI
  98. Herrera-Arellano, 2004, Effectiveness and tolerability of a standardized extract from Hibiscus sabdariffa in patients with mild to moderate hypertension: a controlled and randomized clinical trial, Phytomedicine, 11, 375, 10.1016/j.phymed.2004.04.001 · DOI · Paper page
  99. Herrera-Arellano, 2007, Clinical effects produced by a standardized herbal medicinal product of Hibiscus sabdariffa on patients with hypertension. A randomized, double-blind, lisinopril-controlled clinical trial, Planta Med, 73, 6, 10.1055/s-2006-957065 · DOI
  100. Hirunpanich, 2006, Hypocholesterolemic and antioxidant effects of aqueous extracts from the dried calyx of Hibiscus sabdariffa L. in hypercholesterolemic rats, J Ethnopharmacol, 103, 252, 10.1016/j.jep.2005.08.033 · DOI · Paper page
  101. Chang, 2014, Hibiscus sabdariffa extract inhibits obesity and fat accumulation, and improves liver steatosis in humans, Food Funct, 5, 734, 10.1039/c3fo60495k · DOI
  102. Serban, 2015, Effect of sour tea (Hibiscus sabdariffa L.) on arterial hypertension: a systematic review and meta-analysis of randomized controlled trials, J Hypertens, 33, 1119, 10.1097/HJH.0000000000000585 · DOI · Paper page
  103. Gould, 2002, Do anthocyanins function as antioxidants in leaves? Imaging of H2 O2 in red and green leaves after mechanical injury, Plant Cell Environ, 25, 1261, 10.1046/j.1365-3040.2002.00905.x · DOI · Paper page
  104. Li, 2015, A randomized clinical trial evaluating the efficacy of an anthocyanin-maqui berry extract (Delphinol®) on oxidative stress biomarkers, J Nutr, 145, 742, 10.3945/jn.114.205674 · DOI · Paper page
  105. Davinelli, 2015, A randomized clinical trial evaluating the efficacy of an anthocyanin-maqui berry extract (Delphinol®) on oxidative stress biomarkers, J Am Coll Nutr, 34, 28, 10.1080/07315724.2015.1080108 · DOI
  106. Amin, 2015, Anthocyanins and their physiologically relevant metabolites alter the expression of IL-6 and VCAM-1 in CD40 L and oxidized LDL challenged vascular endothelial cells, Mol Nutr Food Res, 59, 1095, 10.1002/mnfr.201400803 · DOI
  107. Jäger, 2014, Comparative absorption of curcumin formulations, Nutr J, 13, 11, 10.1186/1475-2891-13-11 · DOI · Paper page
  108. Sahebkar, 2014, Are curcuminoids effective c-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis, Phytother Res, 28, 633, 10.1002/ptr.5045 · DOI · Paper page
  109. Sahebkar, 2015, Effect of curcuminoids on oxidative stress: a systematic review and meta-analysis of randomized controlled trials, J Funct Foods, 18, 898, 10.1016/j.jff.2015.01.005 · DOI · Paper page
  110. Panahi, 2014, Antioxidant effects of bioavailability-enhanced curcuminoids in patients with solid tumors: a randomized double-blind placebo-controlled trial, J Funct Foods, 6, 615, 10.1016/j.jff.2013.12.008 · DOI
  111. Panahi, 2014, Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial, Phytother Res, 28, 1461, 10.1002/ptr.5149 · DOI
  112. Panahi, 2012, Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, double-blind, placebo-controlled trial, Br J Nutr, 108, 1272, 10.1017/S0007114511006544 · DOI
  113. Panahi, 2012, A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications, Ann Clin Biochem, 49, 580, 10.1258/acb.2012.012040 · DOI
  114. Sahebkar, 2010, Molecular mechanisms for curcumin benefits against ischemic injury, Fertil Steril, 94, e75, 10.1016/j.fertnstert.2010.07.1071 · DOI
  115. Sahebkar, 2014, Curcuminoids for the management of hypertriglyceridaemia, Nat Rev Cardiol, 11, 123, 10.1038/nrcardio.2013.140-c1 · DOI · Paper page
  116. Zingg, 2013, Molecular mechanisms of hypolipidemic effects of curcumin, Biofactors, 39, 101, 10.1002/biof.1072 · DOI
  117. Sahebkar, 2013, Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome?, Biofactors, 39, 197, 10.1002/biof.1062 · DOI
  118. Hasan, 2014, Curcumin modulation of high fat diet-induced atherosclerosis and steatohepatosis in LDL receptor deficient mice, Atherosclerosis, 232, 40, 10.1016/j.atherosclerosis.2013.10.016 · DOI
  119. Shin, 2011, Long-term curcumin administration protects against atherosclerosis via hepatic regulation of lipoprotein cholesterol metabolism, Mol Nutr Food Res, 55, 1829, 10.1002/mnfr.201100440 · DOI · Paper page
  120. Um, 2013, Curcumin attenuates diet-induced hepatic steatosis by activating AMP-activated protein kinase, Basic Clin Pharmacol Toxicol, 113, 152, 10.1111/bcpt.12076 · DOI
  121. Panahi, 2014, Lipid-modifying effects of adjunctive therapy with curcuminoids–piperine combination in patients with metabolic syndrome: results of a randomized controlled trial, Complement Ther Med, 22, 851, 10.1016/j.ctim.2014.07.006 · DOI
  122. Yang, 2014, Lipid-lowering effects of curcumin in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled trial, Phytother Res, 28, 1770, 10.1002/ptr.5197 · DOI
  123. Mohammadi, 2013, Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial, Phytother Res, 27, 374, 10.1002/ptr.4715 · DOI · Paper page
  124. Yum, 2001, Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions, Anticancer Res, 21, 2895
  125. Bisht, 2009, Systemic delivery of curcumin: 21st century solutions for an ancient conundrum, Curr Drug Discov Technol, 6, 192, 10.2174/157016309789054933 · DOI
  126. Dupasquier, 2007, Dietary flaxseed inhibits atherosclerosis in the LDL receptor-deficient mouse in part through antiproliferative and anti-inflammatory actions, Am J Physiol Heart Circ Physiol, 293, H2394, 10.1152/ajpheart.01104.2006 · DOI
  127. Caligiuri, 2014, Elevated levels of pro-inflammatory oxylipins in older subjects are normalized by flaxseed consumption, Exp Gerontol, 59, 51, 10.1016/j.exger.2014.04.005 · DOI
  128. Ursoniu, 2016, Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Effects of flaxseed supplements on blood pressure: a systematic review and meta-analysis of controlled clinical trial, Clin Nutr, 35, 615, 10.1016/j.clnu.2015.05.012 · DOI
  129. Wang, 2011, Black and green tea consumption and the risk of coronary artery disease: a meta-analysis, Am J Clin Nutr, 93, 506, 10.3945/ajcn.110.005363 · DOI
  130. Islam, 2012, Cardiovascular effects of green tea catechins: progress and promise, Recent Pat Cardiovasc Drug Discov, 7, 88, 10.2174/157489012801227292 · DOI
  131. Serban, 2015, Effects of supplementation with green tea catechins on plasma C-reactive protein concentrations: a systematic review and meta-analysis of randomized controlled trials, Nutrition, 31, 1061, 10.1016/j.nut.2015.02.004 · DOI
  132. Rains, 2011, Antiobesity effects of green tea catechins: a mechanistic review, J Nutr Biochem, 22, 1, 10.1016/j.jnutbio.2010.06.006 · DOI · Paper page
  133. Keske, 2015, Vascular and metabolic actions of the green tea polyphenol epigallocatechin gallate, Curr Med Chem, 22, 59, 10.2174/0929867321666141012174553 · DOI
  134. Zheng, 2011, Green tea intake lowers fasting serum total and LDL cholesterol in adults: a meta-analysis of 14 randomized controlled trials, Am J Clin Nutr, 94, 601, 10.3945/ajcn.110.010926 · DOI
  135. Shishikura, 2006, Effects of tea polyphenols on emulsification of olive oil in a small intestine model system, J Agric Food Chem, 54, 1906, 10.1021/jf051988p · DOI
  136. Lu, 2008, Polyphenol contents of Pu-Erh teas and their abilities to inhibit cholesterol biosynthesis in Hep G2 cell line, Food Chem, 111, 67, 10.1016/j.foodchem.2008.03.043 · DOI
  137. Singh, 2009, Green and black tea extracts inhibit HMG-CoA reductase and activate AMP kinase to decrease cholesterol synthesis in hepatoma cells, J Nutr Biochem, 20, 816, 10.1016/j.jnutbio.2008.07.011 · DOI
  138. Cuccioloni, 2011, Epigallocatechin-3-gallate potently inhibits the in vitro activity of hydroxy-3-methyl-glutaryl-CoA reductase, J Lipid Res, 52, 897, 10.1194/jlr.M011817 · DOI
  139. Puig, 2008, Green tea catechin inhibits fatty acid synthase without stimulating carnitine palmitoyltransferase-1 or inducing weight loss in experimental animals, Anticancer Res, 28, 3671
  140. Way, 2009, Pu-erh tea attenuates hyperlipogenesis and induces hepatoma cells growth arrest through activating AMP-activated protein kinase (AMPK) in human HepG2 cells, J Agric Food Chem, 57, 5257, 10.1021/jf900730e · DOI
  141. Bursill, 2007, A green tea catechin extract upregulates the hepatic low-density lipoprotein receptor in rats, Lipids, 42, 621, 10.1007/s11745-007-3077-x · DOI
  142. Annaba, 2010, Green tea catechin EGCG inhibits ileal apical sodium bile acid transporter ASBT, Am J Physiol Gastrointest Liver Physiol, 298, G467, 10.1152/ajpgi.00360.2009 · DOI
  143. Samman, 2001, Green tea or rosemary extract added to foods reduces nonheme-iron absorption, Am J Clin Nutr, 73, 607, 10.1093/ajcn/73.3.607 · DOI
  144. Shiraishi, 2010, Association between the serum folate levels and tea consumption during pregnancy, Biosci Trends, 4, 225
  145. Alemdaroglu, 2008, Influence of green and black tea on folic acid pharmacokinetics in healthy volunteers: potential risk of diminished folic acid bioavailability, Biopharm Drug Dispos, 29, 335, 10.1002/bdd.617 · DOI
  146. Mazokopakis, 2014, The hypolipidaemic effects of spirulina (Arthrospira platensis) supplementation in a Cretan population: a prospective study, J Sci Food Agric, 94, 432, 10.1002/jsfa.6261 · DOI
  147. Mazokopakis, 2008, Acute rhabdomyolysis caused by spirulina (Arthrospira platensis), Phytomedicine, 15, 525, 10.1016/j.clnu.2015.09.007 · DOI · Paper page
  148. Lee, 2008, A randomized study to establish the effects of spirulina in type 2 diabetes mellitus patients, Nutr Res Pract, 2, 295, 10.4162/nrp.2008.2.4.295 · DOI · Paper page
  149. Park, 2008, A randomized double-blind, placebo-controlled study to establish the effects of spirulina in elderly Koreans, Ann Nutr Metab, 52, 322, 10.1159/000151486 · DOI · Paper page
  150. Ramamoorthy, 1996, Effect of supplementation of spirulina on hypercholesterolemic patients, J Food Sci Technol, 33, 124
  151. Anitha, 2010, Effect of supplementation of spirulina on blood glucose, glycosylated hemoglobin and lipid profile of male non-insulin dependent diabetics, Asian J Exp Biol Sci, 1, 36
  152. Salazar, 1998, Subchronic toxicity study in mice fed Spirulina maxima, J Ethnopharmacol, 62, 235, 10.1016/S0378-8741(98)00080-4 · DOI
  153. Belay, 2002, The potential application of spirulina (Arthrospira) as a nutritional and therapeutic supplement in health management, JANA, 5, 27
  154. Pereira, 2004, Identification of two novel microalgal enzymes involved in the conversion of the ω3-fatty acid, eicosapentaenoic acid, into docosahexaenoic acid, Biochem J, 384, 357, 10.1042/BJ20040970 · DOI
  155. Fares, 2014, Omega-3 fatty acids: a growing ocean of choices, Curr Atheroscler Rep, 16, 1, 10.1007/s11883-013-0389-6 · DOI
  156. Kuratko, 2014, Long–chain omega-3 fatty acids and cardiovascular health, Nutrafoods, 13, 49, 10.1007/s13749-014-0020-7 · DOI
  157. 2014, Fish oil supplements, JAMA, 312, 839, 10.1001/jama.2014.9758 · DOI
  158. Hegele, 2014, The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management, Lancet Diabetes Endocrinol, 2, 655, 10.1016/S2213-8587(13)70191-8 · DOI · Paper page
  159. Taibi, 2014, Practical approaches to probiotics use, Appl Physiol Nutr Metab, 39, 980, 10.1139/apnm-2013-0490 · DOI
  160. Ivey, 2015, The effect of yoghurt and its probiotics on blood pressure and serum lipid profile; a randomised controlled trial, Nutr Metab Cardiovasc Dis, 25, 46, 10.1016/j.numecd.2014.07.012 · DOI
  161. Mitchell, 2008, Conjugated linoleic acid and atherosclerosis: studies in animal models, Biochem Cell Biol, 86, 293, 10.1139/O08-070 · DOI
  162. Mooney, 2012, Effects of conjugated linoleic acid isomers on monocyte, macrophage and foam cell phenotype in atherosclerosis, Prostaglandins Other Lipid Mediat, 98, 56, 10.1016/j.prostaglandins.2011.12.006 · DOI
  163. Castro-Webb, 2012, Cross-sectional study of conjugated linoleic acid in adipose tissue and risk of diabetes, Am J Clin Nutr, 96, 175, 10.3945/ajcn.111.011858 · DOI
  164. Wang, 2004, Conjugated linoleic acid and obesity control: efficacy and mechanisms, Int J Obes Relat Metab Disord, 28, 941, 10.1038/sj.ijo.0802641 · DOI · Paper page
  165. Bialek, 2013, Conjugated linoleic acid as a potential protective factor in prevention of breast cancer, Postepy Hig Med Dosw, 67, 6, 10.5604/17322693.1028764 · DOI
  166. Heinze, 2012, Dietary conjugated linoleic acid and long-chain n-3 fatty acids in mammary and prostate cancer protection: a review, Int J Food Sci Nutr, 63, 66, 10.3109/09637486.2011.598849 · DOI
  167. Gholami, 2014, An overview of conjugated linoleic acid: microbial production and application, Mini Rev Med Chem, 14, 734, 10.2174/1389557514666140820113428 · DOI
  168. Watkins, 2000, Conjugated linoleic acid and bone biology, J Am Coll Nutr, 19, 478S, 10.1080/07315724.2000.10718951 · DOI
  169. Whigham, 2007, Efficacy of conjugated linoleic acid for reducing fat mass: a meta-analysis in humans, Am J Clin Nutr, 85, 1203, 10.1093/ajcn/85.5.1203 · DOI · Paper page
  170. Miranda, 2014, Are conjugated linolenic acid isomers an alternative to conjugated linoleic acid isomers in obesity prevention?, Endocrinol Nutr, 61, 209, 10.1016/j.endonu.2013.04.016 · DOI
  171. López-Barrios, 2014, Bioactive peptides and hydrolysates from pulses and their potential use as functional ingredients, J Food Sci, 79, R273, 10.1111/1750-3841.12365 · DOI
  172. Friedman, 2010, Review of antimicrobial and antioxidative activities of chitosans in food, J Food Prot, 73, 1737, 10.4315/0362-028X-73.9.1737 · DOI · Paper page
  173. Rizzo, 2014, Effects of chitosan on plasma lipids and lipoproteins: a 4-month prospective pilot study, Angiology, 65, 538, 10.1177/0003319713493126 · DOI
  174. Mhurchu, 2004, The effect of the dietary supplement, chitosan, on body weight: a randomised controlled trial in 250 overweight and obese adults, Int J Obes, 28, 1149, 10.1038/sj.ijo.0802693 · DOI
  175. Rahar, 2011, Preparation, characterization, and biological properties of β-glucans, J Adv Pharm Technol Res, 2, 94, 10.4103/2231-4040.82953 · DOI
  176. Wolever, 2010, Physicochemical properties of oat β-glucan influence its ability to reduce serum LDL cholesterol in humans: a randomized clinical trial, Am J Clin Nutr, 92, 723, 10.3945/ajcn.2010.29174 · DOI · Paper page
  177. Kerckhoffs, 2003, Cholesterol-lowering effect of β-glucan from oat bran in mildly hypercholesterolemic subjects may decrease when β-glucan is incorporated into bread and cookies, Am J Clin Nutr, 78, 221, 10.1093/ajcn/78.2.221 · DOI · Paper page
  178. Cleeman, 2001, Expert panel on Detection, Evaluation and Treatment of High blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP III), JAMA, 285, 2486, 10.1001/jama.285.19.2486 · DOI · Paper page
  179. Sood, 2008, Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: systematic review and meta-analysis, Am J Clin Nutr, 88, 1167, 10.1093/ajcn/88.4.1167 · DOI
  180. Onakpoya, 2014, The efficacy of glucomannan supplementation in overweight and obesity: a systematic review and meta-analysis of randomized clinical trials, J Am Coll Nutr, 33, 70, 10.1080/07315724.2014.870013 · DOI
  181. Keithley, 2005, Glucomannan and obesity: a critical review, Altern Ther Health Med, 11, 30
  182. Serban, 2016, Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options, Expert Opin Pharmacother, 17, 369, 10.1517/14656566.2016.1118055 · DOI
  183. Hobbs, 2016, Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro/con debate, BMC Med, 14, 4, 10.1186/s12916-016-0550-5 · DOI · Paper page
  184. Banach, 2015, Lipids, blood pressure and kidney update 2015, Lipids Health Dis, 14, 167, 10.1186/s12944-015-0169-0 · DOI
  185. Michalska-Kasiczak, 2015, Analysis of vitamin D levels in patients with and without statin-associated myalgia—A systematic review and meta-analysis of 7 studies with 2420 patients, Int J Cardiol, 178, 111, 10.1016/j.ijcard.2014.10.118 · DOI
  186. Banach, 2015, Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel, Arch Med Sci, 11, 1, 10.5114/aoms.2015.49807 · DOI · Paper page

Cited by

Metadata

Authors
Sahebkar, A., Serban, M.-C., Gluba-Brzózka, A., Mikhailidis, D. P., Cicero, A. F., Rysz, J., & Banach, M.
Venue
Nutrition
Publisher
Elsevier BV
Published
2016-11
Volume
32
Issue
11-12
Pages
1179-1192
ISSN
0899-9007
DOI
10.1016/j.nut.2016.04.007
Cited by
157
References
31
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.